SCHEMBL4323296

SCHEMBL4323296

COCCN1Cc2cc(-c3cccnc3)cc(C)c2C1=O

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
HTT P42858 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
PARP1 P09874 1/20 0.44
TP53 P04637 1/20 0.43
KDM4E B2RXH2 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MCL1 Q07820 1/20 0.42
PIK3CG P48736 3/20 0.42
POLB P06746 1/20 0.42
CYP11B1 P15538 3/20 0.41
CYP11B2 P19099 3/20 0.41
CYP1A2 P05177 2/20 0.41
CYP17A1 P05093 1/20 0.41
CYP19A1 P11511 1/20 0.41
USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4340783 0.94 HTT (0.47) ALDH1A1SMN1; SMN2HTTNPSR1PARP1
SCHEMBL4342336 0.85 CYP11B2 (0.46) ALDH1A1SMN1; SMN2PIK3CGCYP11B1CYP11B2
SCHEMBL8231100 0.85 PIK3CG (0.46) ALDH1A1SMN1; SMN2PIK3CGCYP11B1CYP11B2
SCHEMBL4329589 0.85 PIK3CG (0.45) ALDH1A1SMN1; SMN2HTTPIK3CGCYP11B1
SCHEMBL4334126 0.83 PIK3CG (0.45) ALDH1A1SMN1; SMN2PIK3CGCYP11B1CYP11B2
SCHEMBL4324337 0.83 PIK3CG (0.41) ALDH1A1SMN1; SMN2PIK3CGCYP11B1CYP11B2
SCHEMBL4324289 0.82 PIK3CG (0.47) PARP1PIK3CGCYP11B1CYP11B2CYP1A2
SCHEMBL2027087 0.81 DHPS (0.55) ALDH1A1SMN1; SMN2PARP1PIK3CGCYP11B1
SCHEMBL4331807 0.81 PIK3CG (0.58) PIK3CGCYP11B1CYP11B2CYP1A2CYP17A1
SCHEMBL2019134 0.81 PIK3CG (0.47) PIK3CGCYP11B1CYP11B2CYP1A2CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149505-A1 Metabotropic Glutamate Receptor-Potentiating Isoindolones ASTRAZENECA AB (SE) 2009-06-11 US claimed
EP-1986998-A1 METABOTROPIC GLUTAMATE RECEPTOR-POTENTIATING SOINDOLONES AstraZeneca AB (SE) 2008-11-05 EP claimed
WO-2007095024-A1 METABOTROPIC GLUTAMATE RECEPTOR-POTENTIATING ΓSOINDOLONES ASTRAZENECA AB (SE) 2007-08-23 WO claimed
US-20090149505-A1 Metabotropic Glutamate Receptor-Potentiating Isoindolones ASTRAZENECA AB (SE) 2009-06-11 US disclosed
US-20090149505-A1 Metabotropic Glutamate Receptor-Potentiating Isoindolones ASTRAZENECA AB (SE) 2009-06-11 US disclosed
US-20090149505-A1 Metabotropic Glutamate Receptor-Potentiating Isoindolones ASTRAZENECA AB (SE) 2009-06-11 US disclosed
EP-1986998-A1 METABOTROPIC GLUTAMATE RECEPTOR-POTENTIATING SOINDOLONES AstraZeneca AB (SE) 2008-11-05 EP disclosed
WO-2007095024-A1 METABOTROPIC GLUTAMATE RECEPTOR-POTENTIATING ΓSOINDOLONES ASTRAZENECA AB (SE) 2007-08-23 WO disclosed
WO-2007095024-A1 METABOTROPIC GLUTAMATE RECEPTOR-POTENTIATING ΓSOINDOLONES ASTRAZENECA AB (SE) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149505-A1 Metabotropic Glutamate Receptor-Potentiating Isoindolones GRM1, GRIN1, GRM3 ALDH1A1 2048/4885SMN1; SMN2 2253/4885HTT 1498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.